The University of Chicago Medicine’s Center for Personalized Therapeutics is hosting a virtual summit from June 9 to July 1 to discuss interventional pharmacoeconomics.
Lyndsey Anderson traveled halfway around the world to do epilepsy research in Sydney, Australia. Recently, she was awarded ILAE's 2020 Epilepsia Prize for Basic Science Research.
It seems there will never be enough “thank you’s” for the incredible doctors, nurses, technicians and support staff members who are working around the clock to help patients with the dangerous coronavirus disease. Their dedication, determination and spirit enable Johns Hopkins to deliver the promise of medicine.
A new class of anticancer agents can restore the ability of cytotoxic T lymphocytes (CTLs) to infiltrate the tumor and kill target cells in patients with metastatic non-small cell lung cancer (mNSCLC).
A drug is being studied for its effectiveness in treating a type of severe immune overreaction seen in patients with COVID-19-induced pneumonia by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
UC San Diego researchers uncovered in mice how IRE1α, a molecule involved in cells’ response to stress, determines whether macrophages promote inflammation in the tumor microenvironment. Inflammation is known to promote tumor growth, making IRE1α an attractive target for drug development.
Loading microparticles with drugs designed to active the macrophages in which TB bacteria hide may lead to therapeutics that can treat drug-resistant and latent TB.
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.
Administering the MMR (measles, mumps, rubella) vaccine could serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection, say a team of experts in this week's mBio, a journal of the American Society for Microbiology.
A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as pre-clinical trials by the University of South Australia show the new formulation improves the drug’s effectiveness by 40 per cent.
The coronavirus pandemic has renewed attention on the Strategic National Stockpile, the nation’s emergency reserve of medical supplies. It’s just one of the stockpiles the United States maintains for economic and strategic purposes.
Nearly 9 in 10 U.S. adults are "very" (55%) or "somewhat" (33%) concerned that the pharmaceutical industry will leverage the COVID-19 pandemic to raise drug prices.
Certain patients who receive hospital care for coronavirus infection (COVID-19) exhibit clinical and neurochemical signs of brain injury, a University of Gothenburg study shows. In even moderate COVID-19 cases, finding and measuring a blood-based biomarker for brain damage proved to be possible.
The Baudry Lab at The University of Alabama in Huntsville (UAH) has identified 125 naturally occurring compounds that have a computational potential for efficacy against the COVID-19 virus from the first batch of 50,000 rapidly assessed by a supercomputer.
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.
At a glance: • Scientists develop AI-based tool to predict adverse drug events • Such events are responsible for some 2 million U.S. hospitalizations per year • The free, open-source system could enable safer drug design, optimize drug safety
SS-31, an experimental drug that has been shown to improve the function of diseased and aged mitochondria, binds to 12 key proteins involved in energy production, researchers at the University of Washington School of Medicine have found.
A Henry Ford Hospital study published in the Journal of Arthroscopic and Related Surgery has found that patients who underwent knee surgery and other types of sports medicine procedures could manage their pain without opioids or a minimal dosage. “This is a large prospective study and our hope is that non-opioid use will gain momentum and that others may tweak our protocol and use it throughout orthopedics, from joint surgery to spine surgery and other surgeries” says Vasilios (Bill) Moutzouros, M.D., chief of Sports Medicine, a division of the Department of Orthopedic Surgery and the study’s lead author.
For the first time, scientists have revealed the steps needed to turn on a receptor that helps regulate neuron firing. The findings might help researchers understand and someday treat addiction, psychosis and other neuropsychological diseases.
Nearly 10 percent of patients who are prescribed opioid medications following heart surgery will continue to use opioids more than 90 days after the procedure, according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania.
combination of IV and oral antibiotics can effectively treat invasive infections in people who inject illicit drugs, according to a study from Washington University School of Medicine in St. Louis. The findings mean that patients who do not wish to stay in the hospital for weeks of IV antibiotic treatment can leave and complete taking their prescribed antibiotics at home.
Funded by the Defense Advanced Research Projects Agency, a team of internationally acclaimed researchers led by UNC School of Medicine’s Bryan L. Roth, MD, PhD, aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects.
A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.
A new study from the University of Notre Dame shows drugs used to treat high cholesterol could interfere with the way breast cancer cells adapt to the microenvironment in the brain, preventing the cancer from taking hold.
Cholesterol levels are declining sharply in western nations, but rising in low- and middle-income nations - particularly in Asia, according to a study of global cholesterol levels, which involve researchers at the University of Gothenburg.
Six months into the COVID-19 pandemic, more than 7.4 million people have been infected, and more than 410 000 have died. As yet, there is no treatment or vaccine for the disease.
Berzosertib, an ATR-targeting drug, improves progression-free survival in combination with chemotherapy in patients with high-grade serous ovarian cancer
Dragana Odobasic, PhD, a research fellow at Monash University in Melbourne, Australia, was awarded the Vasculitis Foundation’s (VF) “Dr. Chris Cox-Marinelli Young Investigator Award” in May for her study, Tolerogenic Dendritic Cells for Antigen-Specific Immunosuppression in MPO-ANCA Vasculitis. The award, a one-year grant totaling $49,822, was created in memory of Chris Cox-Marinelli, MD, who was a strong advocate for promoting the development of junior investigators toward a career in vasculitis.
Israeli researchers have developed an innovative drug delivery system that releases medical cannabis slowly to provide tailored treatment with a long-lasting effect. It could be tailored to specific treatment targets, such as seizures.
A new paper published online in the Annals of the American Thoracic Society examines the nation’s current shortage of vitally needed medications, and how this dangerous situation is being made worse by the COVID-19 pandemic. The authors provide recommendations on how clinicians and institutions might address potential scarcities of essential medications during the current public health crisis.
Researchers at Washington University School of Medicine in St. Louis have developed a mouse model of COVID-19 that is expected to speed up the search for drugs and vaccines for the potentially deadly disease.
In a new study, Johns Hopkins researchers found that testing people for SARS-CoV-2 — the virus that causes COVID-19 — too early in the course of infection is likely to result in a false negative test, even though they may eventually test positive for the virus.
A study of electronic medical records from US Veterans Health Administration medical centers has found that hydroxychloroquine--with or without azithromycin--did not reduce the risk of ventilation or death and was associated with longer length of hospital stay.
Scientists at the University of Liverpool and University of Utrecht have taken another step forward on their quest to develop a viable drug based on teixobactin - a new class of potent natural antibiotic capable of killing superbugs.
The contributions of researchers from The University of Texas at El Paso (UTEP) have yielded the first indication that carbon quantum dots, a class of nanoparticles, can be utilized to combat neurological disorders.
This month’s issue of Toxicological Sciences offers cutting-edge toxicological research in many areas. It includes special features as well as research in developmental and reproductive toxicology; emerging technologies, methods, and models; immunotoxicology; and more.
The June 4, 2020, issue of the weekly Johns Hopkins Medicine research newsletter on topics NOT related to COVID19. Stories this week: study shows pollutant may be more hazardous than previously thought; psilocybin tampers the brain's ego center; and getting urban youth to wear bike helmets.
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.
Rutgers Cancer Institute expert discusses guarding data integrity for the first remdesivir double-blind placebo-controlled clinical trial addressing treatment for COVID-19.
Scientists at Berkeley Lab and Stanford have joined forces to aim a gene-targeting, antiviral agent called PAC-MAN against COVID-19.
Researchers urge a moratorium on prescribing chloroquine or hydroxychloroquine, with or without azithromycin, to treat or prevent COVID-19, and caution that the reassuring safety profile of hydroxychloroquine may be more apparent than real. Safety data derive from decades of prescriptions by clinicians, primarily for their patients with lupus and rheumatoid arthritis, both of which are of greater prevalence in younger and middle age women, who are at very low risk of fatal heart outcomes due to hydroxychloroquine.
Millions of people around the world over the age of 70 are taking at least one medication every day that is causing them more harm than good, leading to falls, confusion, hospitalisation and even death.
ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced that its HEOR Short Course Program is now being offered virtually with 9 upcoming short courses in June and July.
Researchers at Uppsala University and Uppsala University Hospital have developed a new method to measure levels of the medication hydroxychloroquine in patients with the rheumatic disease systemic lupus erythematosus (SLE).
The first patients were treated as part of a clinical trial testing whether an antibody therapy can safely reduce COVID-19 disease severity. The experimental treatment consists of identical copies of an antibody, a blood protein related to those that occur naturally as part of the human immune system, researchers say.
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase 1/2 clinical trial of ADXS-503 being developed by Advaxis, Inc., a new type of cancer therapy which targets “hotspot” mutations that commonly occur in specific cancer types, both by itself and in combination with immunotherapy Keytruda® (pembrolizumab), which is commonly used to treat this type of lung cancer. Dr. Haigentz and colleagues published early results of this study in conjunction with ASCO 2020, the world’s premier scientific meeting for clinical research in oncology.
A new study by investigators from Brigham and Women's Hospital examines changes in prescription patterns in the United States during the COVID-19 pandemic.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right